R&D Projects


Molecular signature in liquid biopsy for active surveillance in prostate cancer

The project aims to develop a combined molecular signature of metabolomics and miRNAs from urine of patients diagnosed with prostate cancer for stratification for active surveillance or immediate intervention. A consortium between the companies Atrys Health (Spain) and DINÁMICA (Colombia) has been established to carry out the project. Both companies will use cohorts of patients diagnosed early with non-aggressive prostate cancer and who meet the criteria for inclusion in active surveillance programmes.

In both cohorts, combined molecular signatures of metabolomic profiles and miRNAs will be sought from samples obtained through non-invasive liquid biopsy procedures from patient urine.


patients participate in the prostate cancer surveillance project


The project aims to develop a molecular signature to predict prostate cancer progression.

In Spain, the study will be carried out on samples collected retrospectively at the Vall d’Hebron Hospital, which will constitute the initial cohort for which the molecular profiles will be analysed in the first discovery phase.

The differential profiles will be validated in the validation cohort formed of patients with active surveillance inclusion criteria in both countries.

To achieve the objectives


In order to successfully achieve the objectives of the project, Atrys partners with DINAMICA (SURA Group), and has the collaboration of the Urology Department of the Vall d’Hebron Hospital and the Medina Foundation.

This project has the support of the CDTI for its funding through the UNILATERAL call for international collaboration projects.

Financial blockers

Related projects